Additional Information for Shareholders

Argent Biopharma Limited

16 December 2024

 

16 December 2024

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

Additional Information for Shareholders

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, wishes to provide holders of the Company's Depositary Interests (DIs) further information regarding their shareholding following the Company's delisting from the Main Market of the London Stock Exchange (LSE).

Upon the delisting event, Argent's shares will cease to be admitted to trading on the LSE, removing the ability to trade through the exchange. The DIs will still be able to settle through the CREST system, which will allow for the depositary interests to be withdrawn from the CREST system and transferred into the Clearing House Electronic Sub-register System (CHESS) which facilitates trade settlements on the Australian Stock Exchange (ASX).  DI holders will be contacted separately regarding any potential future termination of the Depositary Interest facility but should note that in order to settle any trades placed on the ASX they will need to withdraw their DIs and reposition to CHESS, the process for which remains unchanged as a result of the delisting.

The delisting is anticipated to be effective from 08:00 (GMT) on Tuesday, 31 December 2024. The last day of trading of Argent BioPharma shares on the LSE will be Tuesday, 31 December 2024.

Any shareholder that has additional queries around trading is encouraged to approach their investment adviser or broker.

-Ends-

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]

Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]

About Argent BioPharma

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the central nervous system ("CNS") and Immunology treatments.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

END